A Position Statement on Diabetes with β-Cell Failure
	    		
		   		
		   			
		   		
	    	
    	 
    	10.4093/jkd.2024.25.3.124
   		
        
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Ji Yoon KIM
			        		
			        		
			        		
			        			1
			        			
			        		
			        		
			        		
			        		
			        		;
		        		
		        		
		        		
			        		Sang-Man JIN
			        		
			        		;
		        		
		        		
		        		
			        		Gyuri KIM
			        		
			        		;
		        		
		        		
		        		
			        		Soo Kyoung KIM
			        		
			        		;
		        		
		        		
		        		
			        		Won Jun KIM
			        		
			        		;
		        		
		        		
		        		
			        		Sun Joon MOON
			        		
			        		;
		        		
		        		
		        		
			        		Jee Hee YOO
			        		
			        		;
		        		
		        		
		        		
			        		Da Young LEE
			        		
			        		;
		        		
		        		
		        		
			        		Seung-Eun LEE
			        		
			        		;
		        		
		        		
		        		
			        		Ji Eun JUN
			        		
			        		;
		        		
		        		
		        		
			        		Jae Hyeon KIM
			        		
			        		;
		        		
		        		
		        		
		        		
		        		
		        		
		        			
			        		
			        		Author Information
			        		
		        		
		        		
			        		
			        		
			        			1. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Position Statement
 
        	
        	
            
            
            	- From:Journal of Korean Diabetes
	            		
	            		 2024;25(3):124-134
	            	
            	
 
            
            
            	- CountryRepublic of Korea
 
            
            
            	- Language:Korean
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	 Diabetes mellitus is a heterogeneous disease that encompasses a wide range of conditions, from mild cases to severe conditions where survival depends on insulin therapy. The Korean Diabetes Association Task Force Team for Diabetes with β-Cell Failure has established the term to classify severe refractory disease with β-cell failure. Individuals with β-cell failure are at high risk of diabetes-related complications. We propose that diabetes with β-cell failure can be diagnosed when individuals treated with multiple daily insulin injections or insulin pumps meet at least one of the following criteria: fasting C-peptide ≤ 0.6 ng/mL, non-fasting C-peptide ≤ 1.8 ng/mL, 24-hour urine C-peptide < 30 μg/day, or spot urine C-peptide/creatinine ratio ≤ 0.6 nmol/mmol. Among cases of diabetes with β-cell failure, β-cell failure with absolute insulin deficiency can be diagnosed when at least one of the following criteria is met: fasting C-peptide < 0.24 ng/mL, non-fasting C-peptide < 0.6 ng/mL, or spot urine C-peptide/ creatinine ratio < 0.2 nmol/mmol. Multiple daily insulin injections with long-acting insulin analogs and rapid-acting insulin analogs or insulin pumps are required for treatment of diabetes with β-cell failure. Continuous glucose monitoring and an automated insulin delivery system, sensor-augmented pump, or smart insulin pen, along with structured education, are necessary. We call for improvements in the relevant systems to ensure that such treatments can be provided.